Ketamine

Ketamine is a dissociative anesthetic agent that has been a cornerstone of veterinary anesthesia for decades, providing unique pharmacological properties that distinguish it from all other injectable anesthetics available for canine patients. Originally developed as an alternative to phencyclidine (PCP) with improved safety and reduced psychotomimetic effects, ketamine produces a distinctive anesthetic state characterized by profound analgesia, amnesia, and cataleptic immobility while maintaining protective airway reflexes and spontaneous respiration better than other anesthetic agents. The drug's versatility, wide margin of safety, and ability to be administered by multiple routes have made it invaluable across the spectrum of veterinary practice from routine procedures to field anesthesia and emergency medicine.

The primary mechanism of action of ketamine involves non-competitive antagonism of the N-methyl-D-aspartate (NMDA) receptor, a glutamate receptor subtype critical for excitatory neurotransmission and central pain processing. By blocking NMDA receptors, ketamine disrupts the normal integration of sensory information in the thalamus and cortex, producing the characteristic dissociative state where the patient appears disconnected from their environment while maintaining some reflexes and physiological functions. Beyond NMDA receptor antagonism, ketamine has effects on numerous other receptor systems including opioid receptors, monoaminergic systems, and various ion channels that contribute to its complex pharmacological profile including analgesic, antidepressant, and bronchodilatory properties.

Ketamine is available as a sterile injectable solution, most commonly at a concentration of 100 milligrams per milliliter, though other concentrations exist for various applications. The drug can be administered intravenously for rapid onset or intramuscularly when venous access is unavailable or impractical, making it uniquely valuable for situations where other injectable anesthetics requiring intravenous administration cannot be used. Ketamine is highly lipophilic, allowing rapid penetration into the central nervous system and quick onset of dissociative effects. Hepatic metabolism produces active metabolite norketamine, which contributes to the overall clinical effect and influences duration of action, while elimination occurs primarily through renal excretion.

The safety profile of ketamine when used appropriately with proper adjunct medications is excellent, contributing to its continued widespread use despite the availability of newer anesthetic agents. However, ketamine alone produces muscle rigidity, exaggerated reflexes, and potentially alarming movement patterns that necessitate combination with muscle relaxants such as benzodiazepines or alpha-2 agonists for practical use. The drug maintains sympathetic nervous system tone, supporting blood pressure and heart rate in ways that make it valuable for compromised patients but potentially concerning for those with cardiac disease or hypertension. Ketamine is a Schedule III controlled substance requiring appropriate documentation, security, and accountability procedures in veterinary facilities. Veterinary supervision is essential for all ketamine use, with protocols tailored to individual patient needs and clinical circumstances.

Chemical restraint and procedural sedation represent primary applications of ketamine in canine patients, providing sufficient immobilization and analgesia for minor procedures without the full depth of general anesthesia. Wound cleaning, abscess drainage, bandage changes, foreign body removal, and similar interventions can often be accomplished under ketamine sedation combined with appropriate adjunct medications. The drug's ability to be administered intramuscularly makes it particularly valuable for aggressive, feral, or fearful dogs where intravenous catheter placement before sedation is impractical or dangerous. Once adequate sedation is achieved, intravenous access can be established for additional drug administration if needed or for fluid support.

Anesthesia induction using ketamine, typically in combination with benzodiazepines and following appropriate premedication, provides an alternative to propofol or alfaxalone induction in various clinical scenarios. The combination of ketamine with midazolam or diazepam, often preceded by opioid and/or alpha-2 agonist premedication, produces smooth induction suitable for subsequent endotracheal intubation and transition to inhalant maintenance. This approach may be preferred when the sympathomimetic properties of ketamine are desired to maintain cardiovascular function in compromised patients, when rapid intramuscular induction is needed, or when ketamine-based protocols offer logistical or economic advantages for specific practice circumstances.

Multimodal analgesia protocols increasingly incorporate sub-anesthetic doses of ketamine as an adjunct to opioids and other analgesics, particularly for management of severe acute pain and prevention of central sensitization. The NMDA receptor antagonism provided by ketamine blocks wind-up and central sensitization processes that can lead to chronic pain states, making low-dose ketamine infusions valuable during and after major surgical procedures. This analgesic application uses doses far below those required for dissociation, minimizing the characteristic ketamine side effects while contributing meaningful analgesia through a mechanism distinct from opioid or anti-inflammatory drugs.

Field anesthesia and situations where sophisticated monitoring equipment and inhalant anesthesia capability are unavailable represent important applications of ketamine-based protocols. Veterinary practitioners working in shelter settings, during disaster response, for wildlife management involving canids, or in resource-limited environments can safely perform procedures under ketamine anesthesia without the infrastructure required for inhalant techniques. The drug's wide margin of safety, multiple administration routes, and maintenance of protective reflexes provide advantages when optimal monitoring and support capabilities are unavailable. Recovery monitoring remains essential even in field conditions.

Emergency and critical care applications of ketamine include anesthesia for unstable patients and sedation for ventilator management in critically ill dogs. Ketamine's maintenance of sympathetic tone supports cardiovascular function in patients who might not tolerate the cardiovascular depression of other anesthetic agents, though its sympathomimetic effects must be considered in patients with cardiac disease. Low-dose ketamine infusions can provide sedation and analgesia for patients requiring mechanical ventilation while minimizing cardiovascular effects. The drug's bronchodilatory properties may benefit patients with reactive airway disease or bronchospasm requiring anesthesia or sedation.

Ketamine dosing in dogs varies substantially based on the route of administration, concurrent medications, and intended depth and duration of effect. For intravenous induction of anesthesia in combination with a benzodiazepine, typical doses range from 2 to 5 milligrams per kilogram, with lower doses appropriate for premedicated patients and higher doses potentially needed in unpremedicated or resistant individuals. The ketamine and benzodiazepine are often drawn into the same syringe and administered together, with midazolam at 0.2 to 0.3 milligrams per kilogram or diazepam at 0.25 to 0.5 milligrams per kilogram providing muscle relaxation and reducing ketamine dose requirements. Slow intravenous administration over 60 seconds improves induction quality.

Intramuscular administration requires higher doses than intravenous use due to slower absorption and distribution, with typical ranges of 5 to 10 milligrams per kilogram for ketamine combined with 0.25 to 0.5 milligrams per kilogram of midazolam or appropriate doses of alpha-2 agonists. The onset of effect following intramuscular injection is 5 to 15 minutes, substantially longer than the rapid onset after intravenous administration. This route is valuable when intravenous access is unavailable, such as for fractious or feral animals, but requires patience during the induction period and recognition that additional time is needed before attempting procedures. Once sedated, intravenous access can be established for supplemental dosing or other medications.

Sub-anesthetic doses for analgesia typically employ constant rate infusions of 2 to 10 micrograms per kilogram per minute, often following a loading dose of 0.5 milligrams per kilogram. These doses are well below those causing dissociation and are used as adjuncts to opioid and other analgesic protocols for major surgery or severe pain. At these doses, the psychotomimetic effects of ketamine are minimal while meaningful NMDA receptor antagonism contributes to pain management. Analgesic infusions can continue into the post-operative period, though patients should be monitored for any signs of dysphoria or excessive sedation.

Premedication significantly influences ketamine requirements and the quality of resulting anesthesia or sedation. Alpha-2 adrenergic agonists such as dexmedetomidine or medetomidine profoundly reduce ketamine requirements while providing sedation, muscle relaxation, and analgesia that complement ketamine's effects. This combination produces reliable chemical restraint through intramuscular administration for field use or fractious animal handling. Opioid premedication provides analgesia and sedation that reduces ketamine doses while improving overall anesthetic quality. Benzodiazepines are frequently combined with ketamine to counteract muscle rigidity and reduce recovery excitement.

Recovery from ketamine anesthesia differs from recovery from other anesthetic agents, reflecting the unique pharmacology of dissociative anesthesia. Patients may retain eye opening, muscle tone, and some reflexes while remaining unconscious, making assessment of anesthetic depth different from that with other agents. As ketamine effects wane, patients may show ataxia, exaggerated responses to stimuli, and occasionally dysphoria during emergence. Recovery should occur in a quiet, dimly lit environment with minimal stimulation to reduce excitement. Combination with benzodiazepines typically produces smoother recovery than ketamine alone. Full recovery may require 1 to 2 hours depending on doses administered and individual patient factors.

Dose adjustments are necessary in specific patient populations to ensure safety and efficacy. Geriatric patients and those with hepatic dysfunction may require dose reduction due to altered drug metabolism. Patients with renal insufficiency may show prolonged effects due to delayed excretion of ketamine and its metabolites. Neonatal and pediatric patients have immature metabolic pathways that may alter drug handling, though ketamine is generally well-tolerated in young animals. Cats are notably more sensitive to ketamine than dogs and require lower doses per kilogram; practitioners working with multiple species must be aware of these differences to avoid overdosing feline patients.

Cardiovascular stimulation represents one of the most clinically significant effects of ketamine, distinguishing it from other anesthetic agents that typically produce cardiovascular depression. Ketamine maintains or increases sympathetic nervous system activity, resulting in increased heart rate, increased systemic vascular resistance, and maintained or elevated blood pressure. While this sympathomimetic effect is advantageous for maintaining cardiovascular function in compromised patients, it may be undesirable in patients with cardiac disease, particularly those with obstructive conditions or hypertension where increased heart rate and blood pressure increase myocardial oxygen demand. Pre-existing tachycardia or hypertension should prompt consideration of alternative agents.

Muscle rigidity and cataleptic movements are characteristic effects of ketamine that necessitate combination with muscle relaxant drugs for practical use. Ketamine alone produces increased muscle tone, opisthotonus, and exaggerated purposeless movements that interfere with patient positioning, surgical access, and endotracheal intubation. Benzodiazepines including midazolam and diazepam effectively counteract this muscle rigidity while reducing ketamine dose requirements. Alpha-2 agonists similarly provide muscle relaxation along with their sedative and analgesic effects. Ketamine should rarely be used without concurrent muscle relaxant administration in canine patients.

Maintenance of protective reflexes including pharyngeal, laryngeal, and swallowing reflexes represents both an advantage and potential concern with ketamine anesthesia. While retention of these reflexes reduces aspiration risk compared to other anesthetics, they are not fully intact and aspiration remains possible. Additionally, the maintenance of ocular reflexes means that eye position cannot be used to assess anesthetic depth as with other agents. Corneal reflexes are preserved, potentially causing discomfort if the cornea becomes dry during procedures; lubrication is important during ketamine anesthesia. Salivation may be increased, contributing to airway management challenges.

Psychotomimetic effects and emergence reactions including vocalization, agitation, disorientation, and apparent hallucinations can occur during recovery from ketamine anesthesia. These effects are more common in patients emerging without concurrent sedation from benzodiazepines or alpha-2 agonists, emphasizing the importance of combination protocols. A quiet, dimly lit, low-stimulation recovery environment minimizes emergence reactions. Most dogs recover smoothly from ketamine when appropriate adjunct medications are used and environmental factors are optimized, but occasional patients show prolonged dysphoria requiring additional sedation.

Other reported side effects include increased intraocular pressure, making ketamine relatively contraindicated for patients with glaucoma or penetrating eye injuries. Increased intracranial pressure has been reported, though more recent evidence suggests this effect is minimal when ventilation is supported, and ketamine may actually have neuroprotective properties in some circumstances. Apneusis, an abnormal breathing pattern with prolonged inspiratory holds, can occur particularly with rapid intravenous administration. Hyperthermia may develop during ketamine anesthesia, requiring temperature monitoring and intervention if significant elevation occurs. Local tissue irritation at injection sites is uncommon but possible.

Uncontrolled hypertension represents a primary contraindication to ketamine use due to the drug's sympathomimetic effects that further elevate blood pressure and increase cardiovascular workload. Dogs with pheochromocytoma, severe renal disease with hypertensive crisis, or other causes of significant hypertension should not receive ketamine as the cardiovascular stimulation may precipitate stroke, cardiac decompensation, or other hypertensive emergencies. Similarly, tachyarrhythmias are a relative contraindication as ketamine-induced catecholamine release may exacerbate or precipitate dangerous heart rhythms. Pre-anesthetic cardiovascular assessment helps identify patients at risk.

Cardiac conditions characterized by obstruction to ventricular outflow, including hypertrophic cardiomyopathy and certain congenital defects, represent relative contraindications to ketamine. The increased heart rate and contractility produced by ketamine's sympathomimetic effects can worsen dynamic outflow obstruction and increase myocardial oxygen demand beyond supply, potentially causing ischemia or hemodynamic decompensation. While ketamine's maintenance of blood pressure is generally advantageous, the mechanism underlying this effect may be detrimental in specific cardiac conditions. Thorough cardiovascular evaluation and consultation with specialists should guide anesthetic planning in cardiac patients.

Glaucoma and penetrating ocular injuries are contraindications to ketamine due to the drug's ability to increase intraocular pressure. Ketamine-induced increases in intraocular pressure can cause extrusion of ocular contents in penetrating eye injuries or acute decompensation in patients with existing elevated intraocular pressure. Alternative anesthetic protocols that do not affect intraocular pressure should be selected for ophthalmic procedures and patients with ocular disease. The exception may be when the cardiovascular effects of alternative agents pose greater risk than ketamine's ocular effects, requiring careful risk-benefit assessment.

Head trauma with potential for elevated intracranial pressure has traditionally been listed as a contraindication to ketamine, though more recent evidence suggests this concern may be overstated. The historical concern related to ketamine's potential to increase intracranial pressure and cerebral blood flow, which could exacerbate injury in patients with compromised intracranial compliance. However, current evidence suggests that ketamine does not significantly elevate intracranial pressure when ventilation is adequately maintained, and the drug may actually provide neuroprotection through NMDA receptor antagonism. Nevertheless, many practitioners prefer alternative agents for head trauma patients, and ketamine should be used cautiously if at all in this population. Patients with seizure disorders have traditionally been considered at increased risk for ketamine-induced seizures, though evidence for this is limited, and some practitioners use ketamine successfully in epileptic patients.

Drug interactions with ketamine are extensive and clinically important, influencing both the practical aspects of ketamine administration and the safety of combined drug protocols. Benzodiazepines represent the most common and therapeutically important interaction, with midazolam or diazepam routinely combined with ketamine to counteract muscle rigidity, reduce ketamine dose requirements, improve induction and recovery quality, and provide additional sedation and anxiolysis. This synergistic combination has become standard practice for ketamine use in dogs, with the benzodiazepine typically administered simultaneously in the same syringe or immediately before ketamine injection.

Alpha-2 adrenergic agonists including dexmedetomidine, medetomidine, and xylazine produce profound interactions with ketamine that have both advantages and potential concerns. The combination produces reliable, profound sedation or anesthesia suitable for many procedures, with alpha-2 agonists providing muscle relaxation, sedation, and analgesia that complement ketamine's effects. However, alpha-2 agonists produce their own significant cardiovascular effects including initial hypertension, reflex bradycardia, and reduced cardiac output that interact with ketamine's sympathomimetic effects in complex ways. The net cardiovascular effect depends on specific doses and timing, requiring careful monitoring.

Opioid analgesics are commonly combined with ketamine in multimodal anesthetic and analgesic protocols. Opioids provide analgesia through mechanisms complementary to ketamine's NMDA receptor antagonism, and the combination often allows dose reduction of both drug classes while providing superior overall analgesia. When ketamine infusions are used for perioperative analgesia, concurrent opioid administration is typical. The sedative effects of opioids contribute to smoother ketamine anesthesia and recovery, though respiratory depression from opioids should be monitored as ketamine alone maintains respiration better than most anesthetics.

Inhalant anesthetics interact with ketamine primarily through additive central nervous system depression during the transition from ketamine-based induction to inhalant maintenance. The MAC-sparing effects of ketamine on inhalant requirements are modest compared to opioids or alpha-2 agonists, but some reduction in required inhalant concentration occurs. More importantly, the cardiovascular effects of ketamine may partially offset the cardiovascular depression of inhalant agents during early equilibration. Chloramphenicol and other drugs that inhibit hepatic microsomal enzymes may prolong ketamine effect through reduced metabolism, while enzyme inducers such as phenobarbital may accelerate ketamine clearance and shorten duration of effect.

Ketamine administration requires recognition of the drug's unique pharmacological properties and adherence to precautionary measures that ensure safe, effective use. The fundamental precaution for ketamine use is appropriate combination with adjunct medications that counteract its adverse effects, particularly muscle rigidity. Ketamine should rarely if ever be used as a sole anesthetic agent in dogs due to the unacceptable muscle rigidity, cataleptic movements, and poor recovery quality that occur without concurrent muscle relaxant administration. Benzodiazepines or alpha-2 agonists should be available and administered with ketamine in all but exceptional circumstances.

Controlled substance handling requirements apply to ketamine as a Schedule III controlled substance under DEA regulations. Veterinary facilities must maintain appropriate security, documentation, and accountability procedures for ketamine storage and use. Records of ketamine acquisition, administration, and any wastage must be maintained according to regulatory requirements. Regular inventory reconciliation and security audits help ensure compliance and prevent diversion. Staff with access to ketamine should be educated regarding its controlled status and the importance of appropriate handling.

Pre-anesthetic patient evaluation should identify conditions that influence ketamine suitability, including cardiovascular disease, hypertension, ocular conditions, and neurological disorders. Physical examination findings including heart rate, blood pressure when available, and cardiac auscultation help screen for contraindications. The unique cardiovascular effects of ketamine make pre-anesthetic cardiovascular assessment particularly important, as patients who would benefit from ketamine's sympathomimetic properties differ from those who might be harmed by these same effects. Individual patient assessment guides appropriate drug selection.

Recovery environment optimization is essential for smooth emergence from ketamine anesthesia. A quiet, dimly lit space with minimal stimulation reduces the incidence and severity of emergence reactions including dysphoria, vocalization, and agitation. Patients should be monitored throughout recovery but with minimal unnecessary disturbance. Physical restraint may be needed for some patients showing emergence excitement, with additional sedation available if restraint alone is insufficient. Eye lubrication should be maintained as corneal reflexes are preserved but blinking may be reduced.

Specific patient populations warrant enhanced precautions during ketamine use. Geriatric patients may show altered drug metabolism and elimination requiring dose adjustment. Hepatic disease affects ketamine metabolism, potentially prolonging effect. Renal insufficiency delays excretion of ketamine and active metabolites. Brachycephalic breeds require careful airway assessment regardless of anesthetic agent. Cats are substantially more sensitive to ketamine than dogs, requiring lower doses per kilogram; practitioners handling multiple species must verify doses carefully. Exotic canids may have different drug sensitivities than domestic dogs, requiring specialist consultation for appropriate protocols.

Ketamine storage and handling must comply with controlled substance regulations as well as standard pharmaceutical storage requirements. The drug should be stored at controlled room temperature between 20 and 25 degrees Celsius (68 to 77 degrees Fahrenheit), protected from light exposure, and maintained in a secure location accessible only to authorized personnel. Controlled substance storage typically requires locked cabinets or safes with limited key or combination access, though specific requirements vary by jurisdiction. Security measures should prevent unauthorized access while allowing efficient clinical use by authorized veterinary staff.

Controlled substance documentation requirements apply to all aspects of ketamine handling from receipt through disposal. Detailed records must document quantity received, date of receipt, supplier information, and running inventory. Each use must be documented including patient identification, date, quantity administered, administering veterinarian, and any wastage with witness verification. Regular inventory reconciliation, typically performed at least monthly and often more frequently, ensures accountability and allows early detection of any discrepancies. Regulatory inspections may review controlled substance records, and incomplete documentation can result in significant penalties.

Disposal of ketamine must follow DEA-approved methods for controlled substance destruction. Unused ketamine, expired product, and partial vials cannot be disposed of through routine pharmaceutical waste channels. Acceptable disposal methods include reverse distribution to authorized companies, destruction with DEA-approved kits, or other methods specifically approved for controlled substance destruction. Witnessed destruction with documentation of the quantity destroyed, date, method, and witness signatures provides accountability. Most veterinary facilities establish relationships with reverse distributors or utilize approved destruction kits for controlled substance disposal. Records of disposal must be maintained according to regulatory requirements, typically for a minimum of two years. State pharmacy boards and DEA regulations may have specific additional requirements that must be followed, and facilities should consult current regulations to ensure compliance with all applicable controlled substance handling requirements.

Ketamine pharmacology appears consistent across most dog breeds, without the dramatic breed-specific sensitivities that characterize some other drug classes. However, individual patient variation exists, and certain breed-associated conditions influence ketamine suitability or require protocol modification. The MDR1 (ABCB1) gene mutation that affects certain herding breeds and causes sensitivity to various drugs does not appear to significantly affect ketamine pharmacokinetics or safety, as ketamine is not a significant P-glycoprotein substrate. Breeds commonly affected by MDR1 mutations including Collies, Australian Shepherds, and Shetland Sheepdogs can receive ketamine without specific concern for this genetic factor.

Breeds predisposed to cardiac disease require individual assessment of ketamine suitability based on their specific condition rather than blanket breed-based recommendations. Doberman Pinschers and Boxers predisposed to dilated cardiomyopathy may benefit from ketamine's sympathomimetic effects in early disease but be harmed by increased myocardial demand in advanced disease. Cavalier King Charles Spaniels commonly affected by mitral valve disease should have disease severity assessed before anesthetic planning. The decision to use or avoid ketamine in cardiac patients depends on individual patient status rather than breed alone, with echocardiographic evaluation often informing optimal protocol selection.

Brachycephalic breeds including English Bulldogs, French Bulldogs, Pugs, Boston Terriers, and similar breeds require attention to airway management during any anesthetic event, though this relates to their anatomical abnormalities rather than any specific ketamine sensitivity. Ketamine's maintenance of protective airway reflexes may provide some advantage in these breeds, but the reflexes are not fully intact and aspiration risk remains. Experienced personnel, appropriate equipment, and careful monitoring during induction and recovery are essential. Extended recovery monitoring with delayed extubation allows assessment of airway adequacy before fully awakening.

Giant breeds and toy breeds represent extremes of body size requiring attention to accurate dosing and appropriate monitoring intensity rather than breed-specific ketamine sensitivities. Giant breeds require larger total ketamine doses that may have cost implications and require multiple vials. Toy breeds require precise dose calculation with small volumes; accurate scales and appropriate syringes help ensure correct dosing. Small patients are more susceptible to hypothermia during anesthesia, requiring active warming measures. The pharmacokinetics of ketamine appear similar across size ranges, but the physiological reserve of very small or very large patients may differ from average-sized dogs, warranting appropriate monitoring and supportive care tailored to individual patient needs.

Propofol serves as the primary alternative injectable induction agent to ketamine-based protocols, offering rapid, smooth induction and recovery without the muscle rigidity, cataleptic movements, and extended recovery characteristic of ketamine. Propofol acts through different receptor mechanisms than ketamine and produces more profound cardiovascular and respiratory depression, making it less suitable for compromised patients where ketamine's sympathomimetic effects are advantageous. For routine anesthesia in healthy patients, propofol's ease of use and predictable characteristics often make it preferable. The choice between ketamine and propofol depends on individual patient factors, available monitoring, and clinical circumstances.

Alfaxalone provides another alternative induction agent with good cardiovascular stability, smooth induction, and high-quality recovery. Like propofol, alfaxalone lacks the analgesic properties of ketamine and does not produce muscle rigidity. Alfaxalone may be particularly valuable for patients where ketamine's cardiovascular stimulation is undesirable but standard agents would produce excessive cardiovascular depression. The Schedule IV controlled status of alfaxalone adds regulatory considerations compared to propofol, while ketamine's Schedule III status requires the most stringent controlled substance procedures among the three agents.

Tiletamine, available in combination with zolazepam as Telazol, represents another dissociative anesthetic option related to ketamine but with distinct pharmacokinetic characteristics. Tiletamine-zolazepam provides reliable chemical restraint through intramuscular administration with longer duration than ketamine-benzodiazepine combinations. The fixed combination of tiletamine and zolazepam simplifies drug preparation but limits flexibility in adjusting the ratio of components. Recovery from tiletamine may be prolonged compared to ketamine, particularly in patients requiring multiple doses. This combination is particularly valuable for field anesthesia and fractious animal handling where its reliability and convenient formulation offer practical advantages. As with all anesthetic agents, appropriate veterinary guidance should be sought for selection of the most suitable drug for each individual patient and clinical scenario.